A Novel Targeted T-Cell Modulator, Efalizumab, for Plaque Psoriasis
A Novel Targeted T-Cell Modulator, Efalizumab, for Plaque Psoriasis
About this item
Full title
Author / Creator
Publisher
Boston, MA: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
Boston, MA: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Leukocyte-function–associated antigen type 1 (LFA-1) is involved in the pathogenesis of psoriasis. Efalizumab is a humanized monoclonal antibody that binds to LFA-1 and inhibits T-cell activation. This randomized trial demonstrates the efficacy of efalizumab for moderate-to-severe plaque psoriasis. At 12 weeks, 25 percent of patients who received e...
Alternative Titles
Full title
A Novel Targeted T-Cell Modulator, Efalizumab, for Plaque Psoriasis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_71386051
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_71386051
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa030002
